Combo respiratory tests Resp-4

Mobidiag receives CE-IVD for Amplidiag® RESP-4 for simultaneous detection of COVID-19, Flu A, Flu B and RSV

  • Real-time PCR-based test enables high-throughput reliable detection of most prevalent respiratory infections, including COVID-19
  • One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required

FINLAND, Espoo, March 1st, 2021 – Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.

These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The See poster

Coronavirus COVID-19

Mobidiag in the news with an interview with partner AMETEK Haydon Kerk Pittman Motion Solutions

Thanks to the support and involvement of our trusted partners, Mobidiag is being able to bring fast and reliable solutions for growing demand of COVID-19 diagnostics. All of us have a role to play in the fight against this pandemic!
Read full interview of our Instrument Team Manager Régis Melizzi.
For more information about our coronavirus solutions, visit: https://lnkd.in/dKvxwNu

Coronavirus COVID-19

Mobidiag in the news regarding our coronavirus solutions

We recognize our responsibility at Mobidiag to support healthcare systems globally during this extraordinary situation and we are focusing efforts in this endeavor. Learn more about Mobidiag coronavirus solutions.

Hus tuplaa koronatestien määrän, tuloksissa yllättävän suuri epävarmuus – ”Jopa 20 prosenttia voi saada väärän” (Ilta Sanomat – Uutiset, 06/04/20)

Dépistage du coronavirus : le déconfinement, dépendant des tests sérologiques ? (France Bleu, 30/03/20

See poster

Novodiag cartridge picture

Supporting new tools to test for COVID-19: a priority for the EU and its bank

Mobidiag is proud to play an active part in the fight against coronavirus and being supported by the European Commission and European Investment Bank (EIB).

Read Full Article

Virus 3D picture

Mobidiag featured in Finnish magazine Taloussanomat

This article covers Mobidiag joining the fight against coronavirus with innovative diagnostic solutions.

Read Full Article


MTV3 Huomenta Suomi, November 2019 (tv interview)

Mobidiag featured on MTV3 Huomenta Suomi morning show. TV interview focuses on antibiotic resistances and the importance of diagnostics in the fight against antimicrobial resistance and superbateria and how Mobidiag’s diagnostic products are well positioned to tackle this serious issue.

See poster

Helsingin Sanomat for Espoo, November 2019 (web + print pp. 5)

Mobidiag featured on front page of Helsingin Sanomat Espoo edition. Article focuses on all things antimicrobial resistance, molecular diagnostics and manufacturing. Subscribers of Helsingin Sanomat are able to read full article from the link below.

Read Full Article

Shu and Shova_NUH_QMC

Novodiag® CarbaR+ featured in Biomedical Scientist magazine – Complete evaluation by Nottingham University Hospital QMC

The article features the successful evaluation of Novodiag® CarbaR+ conducted by Nottingham University Hospitals, NHS Trust, Clinical Microbiology, Queen’s Medical Centre.

Shova Sharma, Associate Practitioner & Experimental Lead of the evaluation and Su Sewaa, Deputy Service Manager of NUH QMC have recently evaluated the test and their results are featured in this month´s Biomedical Scientist issue. NUH Clinical Microbiology will be publishing poster of the evaluation in October 2019 at EMMD in the Netherlands.


Mobidiag´s Novodiag® CarbaR+ test is one of the finalists at the International Medtech Insight Award 2019

Delighted to announce that Mobidiag´s Novodiag® CarbaR+ test has been shortlisted for Best Technological Innovation: Diagnostics at the 2019 Medtech Insight Awards.

“This Award will recognize the efforts of an individual, team, or company that developed an innovative medical device or diagnostic that makes significant contributions to advancing patient treatment. The judges will be looking for the product that represents the most innovative new approach to care by addressing an unmet clinical need; by changing the practice of health care to be more effective, efficient or less error-prone; or by expanding technology to new patient populations.”

Mobidiag featured in Bonnier Business Forum´s Hoiva&Terveys

Discover a new article in which our CEO Tuomas Tenkanen presents Mobidiag solutions for antibiotic resistance and the recent news in the company.

Mobidiag aims at developing innovative molecular diagnostics for antibiotic resistance – read our CEO’s latest interview on the topic and the company’s future plans.

Read full article in Finnish by clicking here.

Next Page »